The Cancer Letter

Inside information on cancer research and drug development

Regulatory News

FDA tells sponsors of CAR T-cell therapies to add boxed warning about secondary T-cell malignancies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

FDA has directed the sponsors of CAR T-cell therapies to place boxed warnings on their products to indicate that the agents may cause secondary T-cell malignancies. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

CAR T-cell therapy obe-cel demonstrates high response rates in advanced B-cell ALL

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia who were treated with the novel anti-CD19 chimeric antigen receptor T-cell therapy, obecabtagene autoleucel, experienced high response rates and most did not need a subsequent stem cell transplant, according to results from the phase Ib/II FELIX trial co-led by researchers at the University of Texas MD Anderson Cancer Center.
Byline
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account